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Abstract 
BRAF inhibitors are broadly used for metastatic melanoma with BRAF mutations. Their use 
results in various cutaneous side effects, such as the development of keratoacanthomas and 
squamous cell carcinomas. We report a patient with metastatic melanoma treated with 
vemurafenib who developed dozens of histologically confirmed epidermal cysts within 2 
months after initiation of vemurafenib administration. The cystic lesions were observed only 
in the localized area where a large exophytic melanoma tumor mass had been previously 
irradiated. Localized epidermal cysts may constitute an unusual radiation recall reaction in 
patients treated with BRAF inhibitors. © 2014 S. Karger AG, Basel 
Introduction 
Vemurafenib is a BRAF inhibitor widely used as a targeted therapy in BRAF-mutated 
metastatic melanoma [1]. BRAF mutations are present in 40–60% of patients with cutaneous 
melanoma [1, 2], by far the most common mutation being V600E [1–3]. 
Vemurafenib therapy is associated with several cutaneous side effects, including 
palmoplantar erythema, UVA-induced photosensitivity, hyperkeratotic lesions of the soles, 
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development of keratoacanthomas and squamous cell carcinomas as well as new primary 
melanomas [1–5]. Inflammatory cutaneous side effects were reported as early as 3–6 weeks 
after initiation of vemurafenib treatment. So far only a few reports describing radiosensitiza-
tion or radiation recall dermatitis following treatment with BRAF inhibitors exist [6]. 
We report the development of localized epidermal cysts following radiotherapy and 
treatment with vemurafenib. 
Case Report 
A 43-year-old female patient with a recently diagnosed metastatic melanoma, AJCC 
stage IV, was referred for evaluation of cystic lesions on the lateral face and left neck region. 
These cysts had started growing during the previous 6 weeks. The patient initially presented 
with an 8 × 15 cm exophytic pigmented tumor mass in the left inframandibular neck region. 
Light microscopy studies confirmed the diagnosis of melanoma, although it remained un-
clear whether the lesion represented a primary or a local metastasis. Staging exams includ-
ing total body computed tomography showed a pelvic tumor mass 20 cm in diameter with 
diffuse enlargement of mesenteric, paraaortic and cervical lymph nodes. The lesions were 
regarded as lymph node metastases of the melanoma. Magnetic resonance imaging of the 
brain excluded the presence of brain metastases. 
Because of the advanced stage of the tumor palliative, neoadjuvant, hypofractionated 
radiotherapy was started. The exophytic tumor in the neck was given a total radiation dose 
of 30 Gy with 6 × 5 Gy per daily fraction administered 5 days per week. Based on the 
detection of a BRAF mutation V600E in exon 15, the patient was given vemurafenib 
(Zelboraf®) 960 mg twice daily 3 days after completion of the radiotherapy. At the follow-up 
visit 3 months after radiotherapy, the patient was found to have multiple epidermal cysts in 
the previous irradiation field, i.e. the left temple, ear and auditory canal and posterior neck 
region (fig. 1). Light microscopy studies confirmed the diagnosis (fig. 2). At the 1-year 
follow-up visit the patient’s situation was stable and the number of epidermal cysts un-
changed. 
Discussion 
The use of BRAF inhibitors is associated with numerous cutaneous side effects. Most 
notably, BRAF inhibition leads to the formation of squamous cell carcinomas in RAS-primed 
cells due to an activation of the MAPK pathway [3, 7]. Nevertheless, there are few data about 
the side effects related to the combined use of BRAF inhibitors and radiotherapy. 
In our case, the development of cysts limited to a previously irradiated field was highly 
unusual and peculiar in our experience. Even though milia-like epidermal cysts have been 
described in patients treated with the BRAF inhibitor vemurafenib [8], in our case this 
phenomenon was specifically observed only in the irradiated field, suggesting that the ir-
radiation resulted in a localized susceptibility for the side effects of vemurafenib in the 
context of a so-called radiosensitization or radiation recall dermatitis. Nevertheless the  
exact pathomechanisms responsible for a radiation recall dermatitis remain unclear. The 
irradiation is likely to lead to an inflammatory reaction and tissue damage related to the 
release of inflammatory cytokines such as TNF-α, interleukin-1 and interleukin-6 [9]. Ini-
tiation of medicamentous therapy may again trigger a local reaction by releasing these 
cytokines [9]. 
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Previous in vitro studies have shown that simultaneous administration of radiotherapy 
and sorafenib is associated with enhanced cytotoxic effects. It is conceivable that the latter is 
related to radiation-induced DNA damage with a higher cell count in a vulnerable phase of 
the cell cycle together with an additional inhibition of DNA repair by sorafenib [10]. Another 
in vitro model provided evidence that BRAF-positive melanoma cells are radiosensitized 
following BRAF inhibition [11]. In our case, the formation of cystic lesions may be dependent 
on RAS activation [3], as reported for keratoacanthomas and squamous cell carcinoma. 
Only a few similar cases of localized skin reactions in irradiated areas following BRAF 
inhibition have been described so far. In one other case report cystic lesions were observed 
[12]. Boussemart et al. [8, 13] reported two cases of pruriginous skin reactions. Ducassou et 
al. [9] and Satzger et al. [6] reported cases of an asymptomatic erythematous reaction lim-
ited to the irradiated area, an observation suggesting a cutaneous radiosensitization related 
to vemurafenib. Also some cases of severe radiotherapy-induced visceral toxicity were ob-
served [14, 15]. 
Recently, an increasing number of both cutaneous and visceral radiation recall reactions 
have been reported following the administration of BRAF inhibitors. Since little is known 
about the pathogenesis of these side effect conditions, further research in the growing field 
of combined kinase inhibitor treatment with or without radiation has to be undertaken. 
Disclosure Statement 
The authors have no conflict of interest. 
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Fig. 1. Development of several epidermal cysts in the head and neck area where a large exophytic mela-
noma tumor mass had been previously irradiated. 
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Fig. 2. Light microscopy study overview (a) and close-up view (b) of a H&E-stained section of an excised 
epidermal cyst. 
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